Diagnostic Blood Test to Predict Onset of Diabetic Kidney Disease One Step Closer to Launch Across Europe
Ltd (Proteomics International; ASX: PIQ), a medical technology company headquartered in Perth, Australia, has announced the successful transfer of its PromarkerD technology to the laboratories of clinical diagnostics partner, , a spin-out of University College Dublin.
Currently in Europe, diabetes affects 58 million people, a number that is expected to rise to 67 million people by 2045 (International Diabetes Federation). An estimated one in three adults with diabetes already have chronic kidney disease, however, with early intervention it is possible to delay or prevent clinical symptoms of the disease.
is a diagnostic blood test that uses a unique protein 鈥榝ingerprint鈥� to provide an early detection of the onset of diabetic kidney disease. Following the transfer of the technology to Atturos the PromarkerD test is now available as a mass spectrometry laboratory developed test (MS-LDT) to licence partners in the European market.
Proteomics has also announced the launch of PromarkerD in the first European country, Spain following the completion of a licensing deal with Patia Europe. Patia Europe is commercialising PromarkerD with the Laboratory Developed Test (LDT) being offered by Atturos.
The completion of the technology transfer coincides with the recent publication of the results of the PromarkerD clinical validation study in the . In the clinical study PromarkerD correctly predicted 86% of otherwise healthy diabetic patients who went on to develop chronic kidney disease within four years.
Dr Richard Lipscombe, Managing Director, Proteomics International said, 鈥淲e are excited to be able to offer the PromarkerD test in Europe for the first time and are working hard to give patients around the world the opportunity to know their diabetic kidney disease status. With dialysis treatment costing approximately 鈧�80,000 per year, PromarkerD has the potential to save patients and healthcare systems billions of dollars.鈥�
Professor Stephen Pennington, 51黑料 School of Medicine and founder and Chief Scientific Officer, Atturos said, "It is a significant milestone for our two pioneering companies to be expanding the use of mass spectrometry for new clinical diagnostic tests, such as PromarkerD.鈥�
鈥淎tturos had applied the latest generation of analytical instrumentation (Agilent 6495 Triple Quadrupole LC/MS) to make the MS-LDT available and are now in the process of establishing the PromarkerD method into an integrated and automated sample workflow that includes the Agilent Bravo Automated Liquid Handling Platform.鈥�
Atturos, working closely with Proteomics International's scientists, has undertaken a stringent validation process of the PromarkerD method and demonstrated data equivalence in 100 patient samples analysed in both laboratories.
The results of this successful "cross-over" study will be presented in the Precision Medicine and Clinical Proteomics section of the 18th Human Proteome Organization (HUPO) World Congress being held this week in Adelaide, Australia. Professor Pennington is the current President of HUPO.
Proteomics International is in discussions with tier-1 diagnostics and pharmaceutical companies, targeting the markets of Europe, Japan, India and the USA, to expand the global reach of PromarkerD.
The peer-reviewed work published in the Journal of Diabetes and its Complications was conducted in collaboration with the University of Western Australia Medical School. The paper entitled Validation of a protein biomarker test for predicting renal decline in type 2 diabetes: The Fremantle Diabetes Study Phase II, is available online via .
ENDS
16 September 2019
For further information contact Mic茅al Whelan, Communications and Media Relations Manager, Nova51黑料, 51黑料 Research and Innovation, e: miceal.whelan@ucd.ie or t: +353 1 716 3712.
Editors Notes
The PromarkerD test system assesses the risk of diabetic kidney disease in patients with type 2 diabetes. Chronic kidney disease is one of the major complications arising from diabetes and if unchecked can lead to dialysis or kidney transplant. PromarkerD is a simple blood test that uses a unique protein 鈥榝ingerprint鈥� to provide an early detection of the onset of disease. In clinical studies published in leading journals PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years. PromarkerD has received patent protection in multiple jurisdictions including Europe, China, Japan and the USA.
Atturos Ltd is a privately funded clinical diagnostics company developing and commercialising advanced molecular diagnostics solutions to enable clinicians and patients make better healthcare decisions. A University College Dublin spin-out, Atturos was founded initially to commercialise the OCProDx test, a pioneering blood test that can determine whether diagnosed prostate cancer is confined to the prostate or has spread beyond it. The company is actively expanding its portfolio of advanced diagnostic solutions that address areas of significant clinical need.
Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The company specialises in the area of proteomics 鈥� the industrial scale study of the structure and function of proteins. It received the world鈥檚 first ISO 17025 laboratory accreditation for proteomics services and operates from state-of-the-art facilities located on Perth's QEII Medical Campus. The company鈥檚 business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.